Page 164 - Eceptor News Today

In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.

Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.

A new study discusses a new assay method designed by researchers to identify SARS-CoV-2 variants.

A new analysis parses out what scientists currently know about the Delta variant and predicts what the end of the COVID-19 pandemic might look like.

A recent review article published in the journal Advanced Science reviewed the features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Using a physical and materials science perspective, the review also summarizes the most significant variants of SARS-CoV-2 encountered to date as well as possible preventive strategies.

A new study discusses the targeted discovery of NTD-reactive antibodies from an individual who had recovered from SARS-CoV-2 infection.

Seeking to better understand the key role the female hormone estrogen plays in maintaining energy balance and weight control, a group led by researchers at Baylor College of Medicine looked into estrogen interactions with specific brain regions that provide these anti-obesity benefits.

A new study aimed to understand the risk of COVID-19 infection given certain serological parameters, in a group of vaccinated healthcare workers with high rates of exposure to the virus, followed up at 9 months from vaccination.

A new study suggests that coronaviruses such as SARS-CoV-2 depend on a furin cleavage site between the S1/S2 subunits to enhance viral infectivity.

Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients that can block infection from broad strains of SARS-CoV-2 virus in preclinical studies. The study was published today in Nature Communications.